EXSCIENTIA
Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration.
This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in 2019 with Celgene prior to Celgene’s acquisition by Bristol Myers Squibb. Exscientia will take responsibility for AI-design and experimental work necessary to discover drug candidates associated with this collaboration for Bristol Myers Squibb. Molecules will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimized compounds fulfilling complex design goals faster and more effectively than traditional drug discovery.
Andrew Hopkins, CEO of Exscientia, commented, “We are proud that Bristol Myers Squibb wants to build on our work together with this expanded collaboration and believe it speaks to the strength and promise of Exscientia’s AI technologies and drug discovery expertise. We’re excited to work with such an experienced collaborator as Bristol Myers Squibb to develop the best possible medicines for patients .”
Rupert Vessey, President of Research & Early Development at Bristol Myers Squibb said, “We have been pleased with Exscientia’s work in tackling a number of distinct projects for Bristol Myers Squibb. Exscientia’s application of AI technologies is proving capable of generating best-in-class molecules while also reducing discovery times. Rapid discovery of molecules that can enter the clinic in a timely manner could positively impact our work in discovering treatments for areas of unmet medical need ”
Exscientia has already built a strong track record for its drug discovery platform, being the first company to advance AI-designed small molecule drug candidates into clinical studies. In addition to Bristol Myers Squibb, Exscientia has previously entered collaborations with major pharmaceutical companies including Bayer, Sanofi, and Dainippon Sumitomo, multiple emerging biotech companies and the Gates Foundation, demonstrating Exscientia’s reputation as the collaborator of choice for high-value AI-driven drug discovery. The company currently has more than a dozen partnered or wholly owned drugs in development. Exscientia recently secured a $525 million Series D investment, led by Softbank, to further fund expansion of its technology capabilities and proprietary drug pipeline.
About Exscientia
Exscientia’s AI centric, end-to-end drug discovery platform is set to revolutionise the process invention of new drugs, designing therapeutics for areas of high unmet medical need that could positively impact patients, with timelines that are many years shorter than industry standards. As a clinical stage company, Exscientia is the first to advance AI-designed small molecules into a clinical setting, demonstrating the potential of AI to transform the pharmaceutical industry.
Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.
For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 05:25:00 CET | Press release
FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,
Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 04:31:00 CET | Press release
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig
OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 03:00:00 CET | Press release
Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl
Cessna Citation CJ3 Gen2 Enters Into Service, Delivering the Most Significant Gen2 Updates to Date8.1.2026 22:30:00 CET | Press release
The Cessna Citation CJ3 Gen2 has entered into service, setting a new standard for the Citation Gen2 family. Launch customers and longtime Citation owners Dave Mecartney and Shannon Day took delivery of their new aircraft this week. Mecartney—an experienced aviator with nearly two decades flying Citation light jets and a member of Textron Aviation’s Customer Advisory Board—helped shape the enhancements that elevate the CJ3 Gen2 experience. Key upgrades include Garmin autothrottle technology, added pilot legroom and a fully customizable cabin environment, all driven by customer feedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108455097/en/ Cessna Citation CJ3 Gen2 enters into service, delivering the most significant Gen2 updates to date (Photo credit: Textron Aviation). The Cessna Citation CJ3 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Citation CJ3 Gen2 deliv
Andersen Global tilføjer González-Paullada Domínguez i Monterrey, Mexico8.1.2026 22:06:00 CET | Pressemeddelelse
Andersen Global udvider sin latinamerikanske platform gennem en samarbejdsaftale med det Monterrey-baserede advokatfirma González-Paullada Domínguez (GPD) og styrker dermed organisationens tilstedeværelse i Mexico yderligere. GPD blev grundlagt i 2021 og tilbyder omfattende rådgivning inden for både transaktions- og procesretlige forhold. Firmaet rådgiver klienter på tværs af brancher – herunder produktion, ejendom, forsikring, informationsteknologi, minedrift og bankvæsen – om selskabsret, fusioner og opkøb, ejendomstransaktioner, udenlandske investeringer, kommercielle kontrakter, regulatorisk compliance samt løbende juridiske gennemgange. GPD repræsenterer desuden klienter i komplekse civile og kommercielle retssager, voldgiftssager og insolvensbehandlinger. "Monterrey er et væsentligt økonomisk knudepunkt, hvor lokal troværdighed og stærke relationer er afgørende – særligt for udenlandske investorer, der ønsker at etablere sig på markedet," udtaler Alfonso González-Paullada Guerrer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom